Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
Authors
Keywords
-
Journal
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-08
DOI
10.1007/s40262-021-01005-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
- (2021) Chloe Orkin et al. Lancet HIV
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077
- (2020) Cheríe S. Blair et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
- (2020) Raphael J Landovitz et al. Lancet HIV
- HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
- (2020) Kimberly K. Scarsi et al. DRUGS
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Concentration–response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients
- (2019) Nadège Néant et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Management of Virologic Failure and HIV Drug Resistance
- (2019) Suzanne M. McCluskey et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- 2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
- (2019) Parul Patel et al. Open Forum Infectious Diseases
- 1532. Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1-Infected Subjects
- (2019) Kelong Han et al. Open Forum Infectious Diseases
- Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
- (2019) Scott L Letendre et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers
- (2018) Erik Mogalian et al. CLINICAL INFECTIOUS DISEASES
- Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine
- (2018) Nadège Néant et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum
- (2018) Ahizechukwu C. Eke et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals
- (2018) Rebecca Begley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Targeting Metalloenzymes for Therapeutic Intervention
- (2018) Allie Y. Chen et al. CHEMICAL REVIEWS
- Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
- (2018) Maureen Oliveira et al. Retrovirology
- Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling
- (2018) Rajith K R Rajoli et al. JOURNAL OF INFECTIOUS DISEASES
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
- (2018) Pedro Cahn et al. LANCET
- Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence
- (2017) C Orkin et al. HIV MEDICINE
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
- (2017) Adam Trickey et al. Lancet HIV
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
- (2017) Martin Markowitz et al. Lancet HIV
- Life expectancy in HIV-positive persons in Switzerland
- (2016) Aysel Gueler et al. AIDS
- Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women
- (2016) Anna H. Tran et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults
- (2016) Marc Foca et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment
- (2016) Ian McGowan et al. Lancet HIV
- Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
- (2015) Kimberly K. Scarsi et al. CLINICAL INFECTIOUS DISEASES
- Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle
- (2015) John Yin et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)
- (2015) Kerri J. Penrose et al. JOURNAL OF INFECTIOUS DISEASES
- Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
- (2015) David A Margolis et al. LANCET INFECTIOUS DISEASES
- Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam
- (2015) Melinda J. Reese et al. XENOBIOTICA
- Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans
- (2015) Gary David Bowers et al. XENOBIOTICA
- Formulation and pharmacology of long-acting cabotegravir
- (2015) Christine Trezza et al. Current Opinion in HIV and AIDS
- Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
- (2014) Tomokazu Yoshinaga et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
- (2014) A G A Jackson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy
- (2014) B. Mora-Peris et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
- (2014) Pedro Cahn et al. LANCET INFECTIOUS DISEASES
- Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744
- (2013) Susan L. Ford et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
- (2013) W. Spreen et al. HIV CLINICAL TRIALS
- Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro
- (2013) Johanna Weiss et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
- (2013) Hasina Samji et al. PLoS One
- Long-acting injectable antiretrovirals for HIV treatment and prevention
- (2013) William R. Spreen et al. Current Opinion in HIV and AIDS
- Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744
- (2012) Susan L. Ford et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rilpivirine
- (2012) Mark Sanford DRUGS
- Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers
- (2010) J. J. Kiser et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)
- (2008) HM Crauwels et al. Journal of the International AIDS Society
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started